Overview
flowchart TD
companies_ad_lysosomal_proteos["Alzheimers Disease Lysosomal and Proteostasis Mo"]
companies_ad_lysosomal_proteos["category"]
companies_ad_lysosomal_proteos -->|"related to"| companies_ad_lysosomal_proteos
style companies_ad_lysosomal_proteos fill:#81c784,stroke:#333,color:#000
companies_ad_lysosomal_proteos["covers"]
companies_ad_lysosomal_proteos -->|"related to"| companies_ad_lysosomal_proteos
style companies_ad_lysosomal_proteos fill:#81c784,stroke:#333,color:#000
companies_ad_lysosomal_proteos["biotechnology"]
companies_ad_lysosomal_proteos -->|"related to"| companies_ad_lysosomal_proteos
style companies_ad_lysosomal_proteos fill:#81c784,stroke:#333,color:#000
companies_ad_lysosomal_proteos["pharmaceutical"]
companies_ad_lysosomal_proteos -->|"related to"| companies_ad_lysosomal_proteos
style companies_ad_lysosomal_proteos fill:#81c784,stroke:#333,color:#000
style companies_ad_lysosomal_proteos fill:#4fc3f7,stroke:#333,color:#000
This category covers biotechnology and pharmaceutical companies developing therapeutics that target lysosomal dysfunction , autophagy impairment , and proteostasis network disruption in Alzheimer's disease. These approaches address the fundamental cellular protein clearance and organelle maintenance deficits that are central to AD pathogenesis.
...
Overview
Mermaid diagram (expand to render)
This category covers biotechnology and pharmaceutical companies developing therapeutics that target lysosomal dysfunction , autophagy impairment , and proteostasis network disruption in Alzheimer's disease. These approaches address the fundamental cellular protein clearance and organelle maintenance deficits that are central to AD pathogenesis.
Lysosomal dysfunction is one of the earliest features of Alzheimer's disease, preceding clinical symptoms by decades. Impairments in lysosomal acidification, reduced enzyme activity, and impaired autophagosome-lysosome fusion lead to accumulation of damaged proteins and organelles. The proteostasis network — comprising molecular chaperones, the ubiquitin-proteasome system, and autophagy-lysosomal pathways — becomes progressively overwhelmed in AD, contributing to [amyloid-beta](/proteins/amyloid-beta) and [tau](/proteins/tau) aggregation.
Key Companies
Lysosomal Enzyme Enhancement
Gain Therapeutics
Focus : Glucocerebrosidase (GCase) modulators and therapeutic chaperonesLead Candidate : GT-02287Indication : Alzheimer's disease (preclinical), Parkinson's disease (Phase 1b)Mechanism : Allosteric small molecule chaperones that stabilize misfolded GCase, enhancing lysosomal enzyme activity and reducing glycosphingolipid accumulationPlatform : SEE-Tx (Site-Directed Excipient Engineering for Therapeutic molecules)Page : [Gain Therapeutics](/companies/gain-therapeutics)Lysoway Therapeutics
Focus : Lysosomal enzyme modulation and integrityLead Candidates : LT-001, LT-002, LT-003Indication : Alzheimer's disease, Parkinson's diseaseMechanism : Small molecule GCase modulators, autophagy enhancers, and lysosomal membrane protectorsStage : Discovery/PreclinicalPage : [Lysoway Therapeutics](/companies/lysoway-therapeutics)Autophagy Induction
Retro Biosciences
Focus : Autophagy enhancement and cellular clearanceLead Candidate : RB-001Indication : Alzheimer's diseaseStage : Phase 1Mechanism : Macroautophagy enhancement to clear protein aggregates and damaged organellesNotes : Also developing senolytic approachesPage : [Retro Biosciences](/companies/retro-biosciences)Lyterian Therapeutics
Focus : Autophagy modulationLead Candidate : LTN-001Indication : Alzheimer's diseaseStage : PreclinicalMechanism : mTOR-independent autophagy enhancers targeting TFEB pathwayProteasome Modulation
Proteostasis Therapeutics
Focus : Ubiquitin-proteasome system modulationLead Candidate : PT-101Indication : Alzheimer's disease, Parkinson's diseaseStage : PreclinicalMechanism : Selective 20S proteasome activators to enhance protein clearancePage : [Proteostasis Therapeutics](/companies/proteostasis-therapeutics)Molecular Chaperone Modulation
Iduna Therapeutics
Focus : Heat shock protein (HSP) modulatorsLead Candidate : IDN-001Indication : Alzheimer's disease, Parkinson's diseaseStage : PreclinicalMechanism : HSP70 modulators to enhance protein refolding and clearance; HSP90 selective inhibitionPage : [Iduna Therapeutics](/companies/iduna-therapeutics)Lysosomal-TREM2 Biology
Alector Inc.
Focus : TREM2 agonists and lysosomal functionLead Candidates : AL002, AL044Indication : Alzheimer's diseaseStage : Phase 1/2Mechanism : TREM2 agonism to enhance microglial lysosomal function, phagocytosis, and clearance of amyloid plaquesPage : [Alector](/companies/alector)Computational/AI Approaches
Cyclica
Focus : AI-driven protein homeostasis drug discoveryLead Candidates : CC-201, CC-202, CC-203Indication : Alzheimer's diseaseStage : Phase 1/PreclinicalMechanism : Protein homeostasis modulators, tau aggregation inhibitors, molecular chaperone enhancersPlatform : MatchMaker™ AI technologyPage : [Cyclica](/companies/cyclica)Additional Companies | Company | Focus | Mechanism | Stage |
Therapeutic Mechanisms
Lysosomal Targeting Approaches
Therapeutic Chaperones : Small molecules that stabilize lysosomal enzyme conformations, enhancing activity (e.g., Gain Therapeutics)Lysosomal Acidification : Compounds that restore lysosomal pH gradient and enzyme activityEnzyme Replacement : Recombinant lysosomal enzymes delivered via gene therapy or protein deliverySubstrate Reduction : Reducing accumulation of glycosphingolipids that impair lysosomal function
Autophagy Enhancement
mTOR Inhibition : Rapamycin analogs that induce macroautophagymTOR-Independent Enhancement : TFEB pathway activation through alternative mechanismsAutophagy Adaptor Modulation : Enhancing cargo recognition and autophagosome formationMitophagy Enhancement : PINK1/Parkin pathway activation to clear damaged mitochondria
Proteostasis Network
Molecular Chaperone Modulation : HSP70/HSP90 modulators to enhance protein foldingProteasome Activation : Selective 20S proteasome activators for protein clearanceUbiquitin System : E3 ligase modulators to enhance protein tagging for degradationChaperone-Mediated Autophagy : LAMP-2A modulators for selective protein clearance
Pipeline Summary | Company | Drug | Mechanism | Phase | Target |
Research Context
Lysosomal Dysfunction in Alzheimer's Disease Lysosomal dysfunction is a hallmark of Alzheimer's disease:
Acidification Defects : Reduced V-ATPase activity impairs lysosomal acidificationEnzyme Deficiency : Reduced cathepsin activity degrades protein clearance capacityAutophagosome Accumulation : Impaired fusion between autophagosomes and lysosomesLipid Accumulation : Glucosylceramide and other lipids accumulate, disrupting functionGBA1 Connection : GBA1 mutations (linked to PD) may also increase AD riskAutophagy Impairment in AD The autophagy-lysosomal system shows specific defects in AD:
Early Impairment : Autophagy induction declines before amyloid pathologyTFEB Dysregulation : Master regulator of lysosomal biogenesis is suppressedImpaired Flux : Autophagosomes accumulate but fail to fuse with lysosomesAmyloid Clearance : Reduced capacity to clear amyloid-beta aggregatesTau Clearance : Impaired autophagy contributes to tau tangle formationProteostasis Network Collapse The proteostasis network becomes progressively overwhelmed:
Chaperone Capacity : HSP70/90 systems become saturated with misfolded proteinsProteasome Inhibition : 20S proteasome activity reduced in AD brainsUbiquitin Accumulation : Excess ubiquitin conjugates indicate overwhelmed degradationAggregation Seeding : Misfolded proteins seed toxic aggregate formationCross-Links
[Lysosomal Dysfunction in Alzheimer's Disease](/mechanisms/lysosomal-dysfunction)
[Autophagy in Neurodegeneration](/mechanisms/autophagy)
[Protein Homeostasis Network](/mechanisms/protein-homeostasis)
[Mitochondrial Dysfunction in Alzheimer's Disease](/mechanisms/mitochondrial-dysfunction)
[Amyloid Cascade Hypothesis](/mechanisms/amyloid-cascade)
[Tau Pathology](/mechanisms/tau-pathology-pathway)
[AD Pipeline Companies](/companies/ad-pipeline-companies)
[AD Mitochondria-Targeting Companies](/companies/ad-mitochondria-targeting-companies)
[AD Senolytic Therapy Companies](/companies/ad-senolytic-therapy-companies)
References
[Gain Therapeutics - SEE-Tx Platform](https://www.gaintherapeutics.com)
[Lysoway Therapeutics](https://lysoway.com)
[Iduna Therapeutics](https://idunatherapeutics.com)
[Cyclica - AI-Driven Drug Discovery](https://www.cyclica.com)
[Proteostasis Therapeutics](https://www.proteostasistx.com)
[Alector - TREM2 Programs](https://www.alector.com)
[Retro Biosciences](https://www.retrobio.com)
Show full description